Gremubamab

格瑞巴单抗

Report date: 2024/12/04 20:00:29

Base Information

Drug NameGremubamab
Drug Alias NameAnti-Psl/PcrVBiS4alphaPaMEDI-3902
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionPslG inhibitorsType III secretion system protein inhibitors
TargetsType III secretion system proteinPslG
Therapy Area/IndicationsPseudomonas Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumUnited States +[14] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMedimmune
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMedimmune Llc
Active IndicationsN/A
Inactive IndicationsPseudomonas Infections

Other Information

ATC CodeN/A
Related LinksN/A